Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment. Check your account now to learn when your revalidation is due. More information here.

Drugs and Therapeutics (D & T) Committee Meeting Results for: September 14, 2016

Drugs and Therapeutics (D & T) Committee Meeting Results September 14, 2016
Drug Name	Review Type	Committee Recommendation	Prior Approval Status – Final Determination
Viekira XR	New Drug Initial Review	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)
Epclusa	New Drug Initial Review	Preferred with a Prior Approval	Preferred with a Prior Approval
Ocaliva	New Drug Initial Review	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)
Briviact	New Drug Initial Review	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)
Xtampza ER	New Drug Initial Review	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)
Adzenys XR-ODT	New Drug Initial Review	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)
Spinosad	New Drug Initial Review	Remove Prior Approval (Preferred)	Prior Approval Removed (Preferred)
Orenitram ER	New Drug Appeal	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)

Drugs and Therapeutics (D & T) Committee